Earnings
Home›Earnings›Previews›Corvus Pharmaceuticals expands soquelitinib trials ami…
Corvus Pharmaceuticals expands soquelitinib trials amid cash runway
In its Q2 2026 call, Corvus highlighted Phase 1 atopic dermatitis results, including 75% of the highest-dose cohort reaching EASI-75 at 8 weeks.
Corvus Pharmaceuticals (NASDAQ: CRVS) used its second-quarter 2026 earnings call largely to focus on soquelitinib, its oral ITK inhibitor, which the company is testing across five diseases including a rare blood cancer and asthma, according to Yahoo Finance.
For atopic dermatitis, Corvus pointed to data from a Phase 1 trial presented at the Society for Investigative Dermatology meeting. In the highest-dose cohort, 75% of patients reached EASI-75 after 8 weeks on 200 milligram twice-daily dosing versus 20% on placebo, with 25% reaching EASI-90 and about a third achieving clear or almost-clear skin.
The company also said the benefit persisted after dosing stopped, without the rebound it attributed to other drugs in the class. Corvus is carrying the atopic dermatitis data into a roughly 200-patient Phase 2 study, SEERA-1, with enrollment expected to finish in early 2027 and results due the following quarter.
On the financial side, Corvus ended the quarter with $215 million in cash and marketable securities, up from $56.8 million at the end of 2025, largely after raising $189 million in a Q1 follow-on offering. Yahoo Finance reports this funding supports operations into the second quarter of 2028, while Corvus increased R and D spending to $16 million from $7.9 million a year earlier and widened its net loss to $18 million from $8 million as trial costs and headcount tied to soquelitinib rose.
Latest closeNasdaq Comp. 26,729.16 ▼0.3%